Atrasentan is a potent, small molecule inhibitor of the endothelin A receptor. We plan to initiate a Phase 3 clinical trial (ALIGN) of atrasentan in early 2021 for biomarker-selected patients with IgA Nephropathy at high risk for progressive kidney function loss.
BION-1301, a humanized IgG4 monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors, is being evaluated in a Phase 1b trial for IgA Nephropathy patients.
CHK-336 is a potent, small molecule for the treatment of Primary Hyperoxaluria. CHK-336 is currently progressing through IND-enabling studies, with plans for an IND submission in 2021.
One of the key challenges in studying and treating kidney disease has been the complexity of the organ, with nearly 30 distinct cell types, each with its own function and purpose. This cellular diversity and structure has made understanding the mechanisms associated with kidney function loss challenging. However, the recent development of single-cell RNA sequencing of different kidney cell populations presents a new opportunity to clearly understand the molecular mechanisms of kidney function and disease. We utilize single-cell RNA sequencing techniques and proprietary datasets developed by our academic founder, Ben Humphreys (Washington University, St. Louis, MO), to gain unprecedented insights into kidney disease mechanisms.
Chinook’s experienced research and development team has partnered with academic founders and key opinion leaders to identify targets and utilize novel translational technologies to develop precision medicines for kidney diseases.
The cellular complexity of the kidney also presents barriers to developing translationally-relevant models of human kidney diseases. Recently, kidney organoids and patient-derived 3D kidney cellular systems have emerged as advanced preclinical models to study kidney disease. We partner with leading academic collaborators to apply these novel human organoids as translational model systems for target validation in indications such as polycystic kidney disease. In addition, we’ve established patient-derived 3D cellular models of polycystic kidney disease in-house. We believe our approach using these and other validation tools provides significant insights into human disease mechanisms and allows us to select and validate key targets that are central drivers of human kidney diseases.
Our scientific and clinical findings have been presented and published in peer-reviewed forums, and a selection of these have been curated for reference.
We believe science’s greatest achievements were the result of cooperation. Reach out to us to discuss potential collaboration and partnering opportunities if you have interest in advancing drugs to address kidney disease.